{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:24:16Z","timestamp":1781216656375,"version":"3.54.1"},"reference-count":21,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background\/Objectives: Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need. To address this gap, we developed the SUVmax-IPI, a novel prognostic index combining maximum standardized uptake value (SUVmax) from 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) with systemic inflammatory markers. This study aimed to evaluate the prognostic value of SUVmax-IPI in patients with NSCLC receiving nivolumab therapy. Methods: This multicenter retrospective analysis included 187 patients with metastatic NSCLC receiving nivolumab across 5 tertiary institutions. The SUVmax-IPI incorporated pretreatment SUVmax and laboratory-based inflammatory prognostic index (IPI) parameters. Survival outcomes were evaluated using Kaplan\u2013Meier analysis with log-rank testing and multivariate cox regression. Results: Receiver operating characteristic (ROC) analysis established an optimal SUVmax-IPI cut-off of 241.9. Patients with SUVmax-IPI \u2264 241.9 had significantly better survival outcomes: median overall survival (OS) was 35 versus 15 months (p = 0.002). For progression-free survival (PFS), although a numerical difference favored patients with SUVmax-IPI \u2264 241.9 (median: 15 vs. 8 months), this did not reach statistical significance (log-rank p = 0.175). Multivariate analysis confirmed SUVmax-IPI as an independent predictor of survival (p = 0.002). Conclusions: The SUVmax-IPI represents a promising prognostic tool for patients with metastatic NSCLC who received at least 3 months of nivolumab, integrating metabolic and inflammatory parameters to predict survival outcomes.<\/jats:p>","DOI":"10.3390\/curroncol32100566","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:56:29Z","timestamp":1759996589000},"page":"566","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-7212","authenticated-orcid":false,"given":"Nagihan","family":"Kolk\u0131ran","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atike P\u0131nar","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-593X","authenticated-orcid":false,"given":"Mustafa","family":"\u015eahbazlar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Ta\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20070, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-0362","authenticated-orcid":false,"given":"Gamze","family":"G\u00f6k\u00f6z Do\u011fu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20070, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-3926","authenticated-orcid":false,"given":"K\u00fcbra","family":"Canaslan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Dokuz Eyl\u00fcl University, \u0130zmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lkay Tu\u011fba","family":"\u00dcnek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Dokuz Eyl\u00fcl University, \u0130zmir 35330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Demirk\u0131ran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgin","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcler Nur","family":"Tek\u00fcst\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, Mu\u011fla 48000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-7284","authenticated-orcid":false,"given":"\u00d6zg\u00fcr","family":"Tanr\u0131verdi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, Mu\u011fla 48000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrclinonc.2015.75","article-title":"PET in the Management of Locally Advanced and Metastatic NSCLC","volume":"12","author":"Grootjans","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic Activity by 18F-FDG-PET\/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"110200","DOI":"10.1016\/j.ejrad.2022.110200","article-title":"The Role of PET Molecular Imaging in Immune Checkpoint Inhibitor Therapy in Lung Cancer: Precision Medicine and Visual Monitoring","volume":"149","author":"Yao","year":"2022","journal-title":"Eur. J. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Advanced NSCLC","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e22964","DOI":"10.1002\/jcla.22964","article-title":"Systemic Immune-Inflammation Index Predicts Outcomes in Metastatic NSCLC Treated with Nivolumab","volume":"33","author":"Liu","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_11","first-page":"2867","article-title":"Inflammatory Prognostic Index in Resected NSCLC","volume":"19","author":"Tomita","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtcvs.2004.11.007","article-title":"The Maximum Standardized Uptake Values on Positron Emission Tomography of a Non\u2013Small Cell Lung Cancer Predict Stage, Recurrence, and Survival","volume":"130","author":"Cerfolio","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_13","first-page":"2993","article-title":"Prognostic Value of the Standardized Uptake Value Maximum Change Calculated by Dual-Time-Point (18F)-Fluorodeoxyglucose PET Imaging in Patients with Advanced NSCLC","volume":"9","author":"Jin","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2012.47.5947","article-title":"Prediction of Survival by [18F] Fluorodeoxyglucose Positron Emission Tomography in Patients with Locally Advanced NSCLC Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668\/RTOG 0235 Trial","volume":"31","author":"Machtay","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cllc.2019.06.008","article-title":"Incorporation of the SUVmax Measured from FDG PET and Neutrophil-to-Lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients with Locally Advanced NSCLC","volume":"20","author":"Guo","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7137357","DOI":"10.1155\/2022\/7137357","article-title":"Clinical Significance of Serum Biomarkers in Stage IV NSCLC Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB","volume":"2022","author":"Chen","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103806","DOI":"10.1016\/j.critrevonc.2022.103806","article-title":"Prognostic Scores Including Peripheral Blood-Derived Inflammatory Indices in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors","volume":"179","author":"Rebuzzi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/1759-7714.15032","article-title":"Assessing the Role of Colonic and Other Anatomical Sites Uptake by [18F] FDG-PET\/CT and Immune-Inflammatory Peripheral Blood Indexes in Patients with Advanced NSCLC Treated with First-Line Immune Checkpoint Inhibitors","volume":"14","author":"Rizzo","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1080\/07853890.2023.2192047","article-title":"Research Progress and Value of Albumin-Related Inflammatory Markers in the Prognosis of NSCLC: A Review of Clinical Evidence","volume":"55","author":"Zhang","year":"2023","journal-title":"Ann. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhao, K., Wang, C., Shi, F., Liu, H., Wu, S., Ding, H., and Liang, Z. (2021). Combined Prognostic Value of the SUVmax Derived from FDG-PET and the Lymphocyte-Monocyte Ratio in Patients with Stage IIIB\u2013IV NSCLC Receiving Chemotherapy. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07784-x"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ke, L., Lu, S., Li, X., Fan, Y., Zhou, C., Cheng, Y., Wu, L., Yang, Y., Hu, C., and Zhang, L. (2021). Prognostic Significance of SUVmax Combined with Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Plus Chemotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.652312"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/566\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:45Z","timestamp":1760035845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["curroncol32100566"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32100566","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}